Tolerability of different pharmacotherapeutic methods with aliskiren and nebivolol in hypertensive patients
DOI:
https://doi.org/10.24959/cphj.14.1313Keywords:
arterial hypertension, aliskiren, nebivolol, combined useAbstract
It has been proven that monotherapy with aliskiren (150-300 mg/day) and nebivolol (5-10 mg/day) provides hypertensive patients of stage II (essential hypertension) with effective decline of office systolic (SP) and diastolic (DP) blood pressure values to normotonic ones at the end of week 4 of their treatment. The use of combined therapy (aliskiren 150 mg/day + nebivolol 5 mg/day) effectively reduces the indicators of SP and DP at the end of week 2 of their treatment. It has been shown that when conducting different pharmacotherapies (aliskiren 150-300 mg/day; nebivolol 5-10 mg/day; aliskiren 150 mg/day + nebivolol 5 mg/day) none of patients discontinued the treatment due to “unsatisfactory” tolerability for the 8 week period. Neither “unsatisfactory” nor “satisfactory” tolerability of treatment was registered for any variant. The same number of patients in the groups assessed tolerability as “excellent” and “good”. There was no statistically significant difference of distribution of the patients’ assessment of the treatment tolerability for all groups of comparison (p>0.05). From 16.3% to 20.0% of patients of all groups experienced different complaints within 8 weeks of treatment. The rate of complaints was insignificant, once or twice per month, and it was nearly the same during the whole period of treatment. There were no statistically significant changes of the rate at different stages of treatment (p>0.05). In all cases the complaints of the patients of all groups were the following: “headache”, “fatigability”, and “nausea”, “dry cough” and “sleep disturbances”. These complaints were recurrent and didn’t affect the patients. There was no need to stop the treatment due to the side effects. All the patients’ complaints were foreseen because they were stated by the manufactures as the side effects. During the whole study the forms of statistical account of all side effects #137-y were filled out and submitted to the Department of Post-registration Supervision of the State Expert Centre of the Ministry of Health of Ukraine. There were no statistically significant differences of the parameters during the analysis of variance. These results prove that the changes revealed have the random disposition and are not regular, i.e. the results belong to one parent universe.
References
Адашева Т.В., Задионченко В.С., Гринева З.О. и др. // Мед. совет. – 2011. – №1-2. – С. 41-43.
Амосова Е.Н. // Укр. кардіол. журн. – 2006. – №1. – С. 19-25.
Андрєєв Є.В. // Серце і судини. – 2008. – №1 (21). – С. 6-8.
Беловол А.Н. // Biomedical and Biosocial Anthropology. – 2010. – №14. – C. 106-111.
Березин А.Е. // Укр. мед. часопис. – 2009. – №6 (74). – С. 58-65.
Дзяк Г.В., Ханюков А.А., Писаревская О.В. и др. // Укр. мед. часопис. – 2009. – №1 (69). – С. 17-25.
Директивы по диагностике и лечению артериальной гипертензии 2007 (сокр. излож.) / Рабочая группа по диагностике и лечению артериальной гипертензии // Медицина світу. – 2007. – Т. XXIII, №1. – С. 20-39.
Жарінов О.Й. // Серце і судини. – 2007. – №1 (17). – С. 8-13.
Казаков В.Н., Лях Ю.Е., Кутько И.И. и др. Теоретические и практические аспекты автоматизированной информационной системы «Депрессии» / Серия «Очерки биологической и медицинской інформатики». – Донецк: Изд-во ДонГМУ, 2007. – 160 с.
Карпов Ю.А. // Рус. мед. журн. – 2008. – №16 (21). – С. 1145-1448.
Кобалова Ж.Д., Котовская Ю.В., Виллевадьде С.В. // Кардиол. – 2008. – Т. 48, №2. – С. 72-87.
Коваленко В.М., Сіренко Ю.М., Дорогой А.П. // Укр. кардіол. журн. – 2005. – №1. – С. 9-15.
Ковалёва О.Н., Шаповалова С.А. Фармакотерапия гипертонической болезни. – Х., 2005. – 136 с.
Лях Ю.Е., Гурьянов В.Г. // Укр. журн. телемедицини та мед. телематики. – 2012. – Т. 10, №2. – С. 69-76.
Лях Ю.Е., Гурьянов В.Г., Хоменко В.Н., Панченко О.А. Основы компьютерной биостатистики. Анализ информации в биологии, медицине и фармации статистическим пакетом MedStat. – Донецк: Папакица Е.К., 2006. – 214 с.
Мысниченко О.В., Коваль С.Н. // Укр. терапевтичний журн. – 2009. – №2. – С. 57-62.
Петри А., Сэбин К. Наглядная статистика в медицине / Пер. с англ. В.П.Леонова. – М.: ГЭОТАР- МЕД, 2003. – 144 с.
Charlos M., Ferrario N. // Am. J. of Therapeutics. – 2004. – Vol. 11. – P. 44-53.
Elliott W.J. // Curr. Probl. Cardiol. – 2007. – Vol. 32, №4. – P. 201-259.
Francesco Cappuccio P., Sally Kerry M., Forbes Lindsay et al. // Lancet. – 2003. – Vol. 362, №1. – Р. 527-535.
Lee D.S., Ghosh N., Floras J.S. et al. // Circ. Heart Fail. – 2009. – Vol. 2, №6. – P. 616-623.
Nalyotova O.S. // Biomed. Markers and Guided Therapy. – 2014. – Vol. 1, №2. – P. 49-58.
Wiens M., Etminan M., Gill S. et al. // J. Intern. Med. – 2006. – Vol. 260, №4. – P. 350-362.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
